- The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks.
- The P-III COAST-X study results: @16 & 52wks. met its 1Eps & 2Eps; improvement in the signs and symptoms of nr-axSpA; improvement in ASDAS & BASDAI; patients achieve low disease activity (ASDAS <2.1); improvement in SIJ; improvement in SF-36 Physical Component Summary (PCS) score; no new safety signals observed
- Taltz (ixekizumab) is a mAb, targeting interleukin 17A (IL-17A) cytokine by inhibiting its interaction with the IL-17 receptor and is under FDA review for radiographic axSpA with its expected regulatory action in H2’19
Click here to read full press release/ article | Ref: Eli Lilly | Image: Fortune